+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2015-06-12Number of Pages: 68

Heparin Market (Unfractionated Heparin, Low Molecular Weight Heparin & Ultra Low Molecular Weight Heparin) - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022


This report provides in-depth analysis of the heparin market in Europe. Stakeholders for this report include manufacturers of heparin products, crude heparin suppliers, heparin processing companies, and new players planning to enter the market.

The report provides qualitative and quantitative analysis of the heparin market in Europe. Qualitative analysis comprises market dynamics, trends, product overview, and country-level market information. Quantitative analysis includes market share held by companies in 2013, market size, and forecast for heparin product types across five major nations in Europe from 2012 to 2022. Market revenue is provided in terms of USD million from 2012 to 2022 along with the compound annual growth rate (CAGR %) from 2014 to 2022 for all the segments, considering 2013 as the base year. The executive summary of the report provides a snapshot of the heparin market in Europe with information on leading segments with respect to the market size, forecast value, market share of key players, growth rate (CAGR %) from 2014 to 2022, and growth factors. 

The market overview section comprises impact factors such as drivers, restraints, and opportunities for the heparin market in Europe. This factors would aid the stakeholders in establishing a strong foothold in the European heparin market. Furthermore, the market overview section comprises market attractiveness and value chain analysis. The market attractiveness analysis section provides a graphical view comparing the growth and market dynamics in different countries to identify the most attractive market for the period from 2014 to 2022. Value chain analysis offers detailed information on value addition activities in the manufacturing process of heparin-based pharmaceutical products.

Market share analysis is also provided in the market overview section of the report for the year 2013 in terms of value (%). Furthermore, the report analyzes different heparin product types such as unfractionated heparin, low molecular weight heparin, and ultra-low molecular weight heparin. The product type section provides market analysis for different types of heparin in Europe. This includes an overview of product types, indications for use, presence of any biosimilars, market drivers, issues, and regulations amended for its production and use. Prices of products vary based on product type and formulation. Formulations with different heparin concentrations and formulation type carry different prices across the countries in the European Union. Hence, the report provides average pricing analysis (based on the current prices) to offer an overview of prices of heparin-based pharmaceutical products in the EU.

The report further provides market analysis for heparin in five major countries in the EU: the U.K., Germany, France, Italy, and Spain. Market analysis for different heparin types is provided for each of these countries from 2012 to 2022 along with the CAGR from 2014 to 2022. The market has been estimated for finished heparin formulation and has not considered its APIs. Major factors such as aging population and increasing prevalence of venous thromboembolism (VTE) that propel the market for heparin in Europe are elaborated in the country-level analysis. This section also covers certain regulations governing the manufacture and import of heparin in some countries.

Major players operating in the heparin market in Europe such as Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Leo Pharma A/S, Pfizer, Inc., Sanofi S.A., and Syntex S.A. are profiled in this report. The report also provides important recommendations for these players and new entrants. These recommendations would enable the existing market players to expand their market share and help new companies establish their presence in the heparin market in Europe.

The Europe Heparin Market is segmented into the following categories: 

Europe Heparin Market, by Product
  • Unfractionated Heparin
  • Low Molecular Weight Heparin (LMWHs)
  • Ultra-low Molecular Weight Heparin (ULMWHs)
Europe Heparin Market, by Country
  • United Kingdom
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWHs)
    • Ultra-low Molecular Weight Heparin (ULMWHs)
  • Germany
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWHs)
    • Ultra-low Molecular Weight Heparin (ULMWHs)
  • France
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWHs)
    • Ultra-low Molecular Weight Heparin (ULMWHs)
  • Spain
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWHs)
    • Ultra-low Molecular Weight Heparin (ULMWHs)
  • Italy
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWHs)
    • Ultra-low Molecular Weight Heparin (ULMWHs)
  • Rest of the Europe
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWHs)
    • Ultra-low Molecular Weight Heparin (ULMWHs)


Chapter 1 Introduction
1.1 Report Description
1.2 Research Methodology
     1.2.1 Secondary Research
     1.2.1 Primary Research
1.3 Assumptions and Stipulations
1.4 Market Segmentation

Chapter 2 Executive Summary

Chapter 3 Market Overview
3.1 Introduction
3.2 Market Drivers
     3.2.1 Rising incidence of coagulation and renal disorders in Europe to propel demand for heparin products
     3.2.2 Ban on imports from China to boost production in European
     3.2.3 Inclination of slaughterhouse owners to enter crude heparin processing business expected to overcome demand supply gap in Europe
3.3 Market Restraints
     3.3.1 Presence of alternatives such as synthetic heparin and other anticoagulants impeding sales of biological-based heparin products
     3.3.2 Enhanced quality control measures and environmental factors elevating the cost of heparin production
3.4 Market Opportunities
     3.4.1 Biosimilars as an alternative to biological based products
     3.4.2 Research activities on marine-based heparin products
3.5 Value Chain Analysis: Europe Heparin Market
3.6 Market Attractiveness Analysis: Europe Heparin Market, by Country
3.7 Market Share Analysis: Europe Heparin Market, by Key Players, 2013
3.8 Average Pricing

Chapter 4 Europe Heparin Market, by Product
4.1 Introduction
     4.1.1 Europe Heparin Market Revenue, by Product, 2012 – 2022 (USD Million)
4.2 Unfractionated Heparin
     4.2.1 Europe Unfractionated Heparin Market Revenue, 2012 – 2022 (USD Million)
4.3 Low Molecular Weight Heparin
     4.3.1 Europe Low Molecular Weight Heparin Market Revenue, 2012 – 2022 (USD Million)
4.4 Ultra-low Molecular Weight Heparin
     4.4.1 Europe Ultra-low Molecular Weight Heparin Market Revenue, 2012 – 2022 (USD Million)

Chapter 5 Europe Heparin Market, by Country
5.1 Overview
     5.1.1 Europe Heparin Market Revenue, by Country, 2012 – 2022 (USD Million)
     5.1.2 United Kingdom
             5.1.2.1 United Kingdom Heparin Market Revenue, by Product, 2012 – 2022 (USD Million)
     5.1.3 Germany
             5.1.3.1 Germany Heparin Market Revenue, by Product, 2012 – 2022 (USD Million)
     5.1.4 France
             5.1.4.1 France Heparin Market Revenue, by Product, 2012 – 2022 (USD Million)
     5.1.5 Spain
             5.1.5.1 Spain Heparin Market Revenue, by Product, 2012 – 2022 (USD Million)
     5.1.6 Italy
             5.1.6.1 Italy Heparin Market Revenue, by Product, 2012 – 2022 (USD Million)
     5.1.7 Rest of Europe (RoE)
             5.1.7.1 Rest of Europe Heparin Market Revenue, by Product, 2012 – 2022 (USD Million)

Chapter 6 Recommendations
6.1 Perform Quality Measures
6.2 Commercializing Biosimilars at a Lower Cost to Increase its Preference Over the Branded Products

Chapter 7 Company Profiles
7.1 Dr. Reddy’s Laboratories Ltd.
     7.1.1 Company Overview
     7.1.2 Financial Overview
     7.1.3 Product Portfolio
     7.1.4 Business Strategies
     7.1.5 Recent Developments
7.2 Fresenius Kabi AG
     7.2.1 Company Overview
     7.2.2 Financial Overview
     7.2.3 Product Portfolio
     7.2.4 Business Strategies
     7.2.5 Recent Developments
7.3 GlaxoSmithKline plc
     7.3.1 Company Overview
     7.3.2 Financial Overview
     7.3.3 Product Portfolio
     7.3.4 Business Strategies
     7.3.5 Recent Developments
7.4 Leo Pharma A/S
     7.4.1 Company Overview
     7.4.2 Financial Overview
     7.4.3 Product Portfolio
     7.4.4 Business Strategies
     7.4.5 Recent Developments
7.5 Pfizer, Inc.
     7.5.1 Company Overview
     7.5.2 Financial Overview
     7.5.3 Product Portfolio
     7.5.4 Business Strategies
     7.5.5 Recent Developments
7.6 Sanofi S.A.
     7.6.1 Company Overview
     7.6.2 Financial Overview
     7.6.3 Product Portfolio
     7.6.4 Business Strategies
     7.6.5 Recent Developments
7.7 Syntex S.A.
     7.7.1 Company Overview
     7.7.2 Financial Overview
     7.7.3 Product Portfolio
     7.7.4 Business Strategies
     7.7.5 Recent Developments

List of Figures

FIG. 1 Europe Heparin Market Segmentation
FIG. 2 Europe Heparin Market, by Geography, 2013 (USD Million)
FIG. 3 Value Chain Analysis: Europe Heparin Market
FIG. 4 Market Attractiveness Analysis of the Europe Heparin Market, by Country
FIG. 5 Market Share Analysis: Europe Heparin Market, by Key Players, 2013 (Value %)
FIG. 6 Europe Unfractionated Heparin Market Revenue,  2012 – 2022 (USD Million)
FIG. 7 Europe Low Molecular Weight Heparin Market Revenue, 2012 – 2022 (USD Million)
FIG. 8 Europe Ultra-low Molecular Weight Heparin Market Revenue, 2012 – 2022 (USD Million)
FIG. 9 United Kingdom Heparin Market Revenue, by Product, 2012 – 2022 (USD Million)
FIG. 10 Germany Heparin Market Revenue, by Product, 2012 – 2022 (USD Million)
FIG. 11 France Heparin Market Revenue, by Product, 2012 – 2022 (USD Million)
FIG. 12 Spain Heparin Market Revenue, by Product, 2012 – 2022 (USD Million)
FIG. 13 Italy Heparin Market Revenue, by Product, 2012 – 2022 (USD Million)
FIG. 14 Italy Heparin Market Revenue, by Product, 2012 – 2022 (USD Million)
FIG. 15 Dr. Reddy's Laboratories Ltd.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 16 Fresenius Kabi: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 17 GlaxoSmithKline plc: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 18 LEO Pharma A/S: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 19 Pfizer, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 20 Sanofi S.A. : Annual Revenue, 2011 – 2013 (USD Million)

List of Tables

TABLE 1 Market Snapshot: Europe Heparin Market
TABLE 2 Europe Heparin Market, Average Prices, 2015 and 2022 (USD)
TABLE 3 Europe Heparin Market Revenue, by Product, 2012 – 2022 (USD Million)
TABLE 4 Europe Heparin Market Revenue, by Country, 2012 – 2022 (USD Million)


Heparin is a sulfated glycosaminoglycan of mixed composition, released by the mast cells and blood basophils. It is used as the calcium or sodium salt in the prophylaxis and treatment of clotting disorders, blood transfusion, and blood sampling. Heparin augments the activity of anti-thrombin III, a natural compound that inhibits activated clotting factors. Furthermore, heparin has been found to inhibit substances that may contribute to angiogenesis, including vascular endothelial growth factor, tissue factor, and platelet-activating factor. 

The Europe heparin market has been studied from two perspectives: by products and by countries. Based on products, the market has been segmented into three categories: unfractionated heparin, low-molecular weight heparin (LMWH) and ultra-low molecular weight heparin (ULMWH). Unfractionated heparin is an anionic mixture of highly sulfated linear glucosamine-glycans having molecular weight ranging from 3,000 to 30,000 Da. Unfractionated heparin as anti-coagulants is majorly consumed in hospitals as prophylaxis or treatment of thrombotic disorders and dialysis. Occurrence of bleeding disorders and low application areas are among the key restraints to the unfractionated heparin market in the Europe. LMWHs are extracted by the enzymatic or chemical depolymerization of unfractionated heparin. Pertaining to high demand for LMWHs during various surgical procedures and treatment of venous thromboembolism (VTE) disease, its demand is anticipated to grow in forthcoming years. Ultra-low molecular weight heparin has molecular weights less than 4000 Da with enhanced anticoagulation activity as compared to low molecular weight heparin. Majority of the research and development activities in Europe are intended to compare the activities of ULMWHs with LMWHs in cancer and neurological disorders which if receives market approval will have positive impact on the Europe heparin market. However high cost of ULMWHs would be a major drawback for the sales of product in near future.

Geographically the market has been segmented into EU5 countries i.e. United Kingdom, France, Italy, Spain, Germany and Rest of the Europe. The German heparin market in 2013 accounted for the largest market share due to high demand for LMWHs and unfractionated heparin products. Moreover, number of surgical procedures such as cardiovascular surgeries, knee and hip replacement and Caesarean sections among others that are performed in Europe is relatively higher as compared to other European countries. Followed by Germany is France where the heparin market is growing rapidly due to increasing incidence and prevalence of coagulation disorders over the last few years. Astonishingly, France being a conservative market, the consumption of unfractionated heparin is high as compared to other EU5 countries. However, in forthcoming years the market will follow trends similar to Germany, especially with respect to LMWHs. 

According to the NHS, one in three patients who undergo hip or knee replacement without thrombophylaxis develops asymptomatic DVT, while one in 30 suffer from symptomatic VTE. Recently, chief medical officer (CMO), the Department of Health in the U.K. published an operating framework which requires risk assessment to be done for thrombosis in a minimum of 90% of patients admitted to hospitals. Such factors would propel the demand and growth of heparin in the U.K. Spain and Italy market have low contribution among the EU5 countries with respect to market revenues. The United Nations (UN) projects that Spain would be the world’s oldest country by 2050. This is a major factor attributed to an increased risk of thrombosis, which would further propel demand for heparin in the region as aging is proportional to incidence of VTE. Major players in the heparin market in Europe such as Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Leo Pharma A/S, Pfizer, Inc., Sanofi S.A., and Syntex S.A. Recently in 2013, GSK’s divested and sold its heparin products Fraxiparine and Arixtra product to Aspen Pharma. 

europe-heparin-market


A complete brochure for this research is available for download.

Interact with our pool of experienced analysts for any report related queries